2025 Q4 -tulosraportti
Vain PDF
91 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·13 t sittenWhen can we realistically expect data? Based on how similar preclinical collaborations normally develop (integration → in vitro → in vivo → analysis), my speculative timeline looks like this: Top-5 Pharma (CNS/AAV) Start: November 2025 Expectation: Q3–Q4 2026 University of Texas Start: January 2026 Expectation: Q4 2026 – Q1 2027 United Immunity (CAR-M) Start: March 2026 Expectation: Q4 2026 Acuitas (LNP/CAR-T) Start: April 2026 Expectation: Q4 2026 TraffikGene Start: April 2026 Expectation: Q1 2027 AaviGen (Heart) Start: May 2026 Expectation: Q4 2026 – Q1 2027 GenAssist Start: June 2026 Expectation: Q1–Q2 2027 Tcelltech Start: June 2026 Expectation: Q1 2027 ⸻ Why do I think this? The Top-5 Pharma collaboration is the best reference. It was announced in November 2025, went from in vitro to in vivo after around five months, and the company has guided towards updates in H2 2026. Looking at similar preclinical collaborations in biotech, it normally takes 6–12 months from when a collaboration is announced until the first meaningful in vivo data arrives. Complete datasets or publications often come later. My conclusion: H2 2026 will probably be the start of the news flow. 2027 could be the year when the majority of collaborations start to deliver results. This is only a qualified speculation based on normal development times in preclinical biotech and publicly available information – not the company's own guidance.
There will probably be updates on sub-phases earlier than the "final" results. Many other things can also come besides these projects, I do not rule out updated circVec 5 with new functionalities, agreements etc.- ·15 t sitten · MuokattuCircio is facing an autumn full of results. If one takes a look back in time, from when the news about the collaboration with Big Pharma came in November 2025 until July 2026, there are a few things that strike one. A number of news items about collaboration projects etc. have emerged, but limited concrete results have been released. New collaborations: Nov 2025 - Feasibility study CNS /AAVV 2026 January - University of Texas - vaccines/infectious diseases March - United Immunity - CAR-M cell therapy April - Acuitas - new LNP - CAR-T - CD8+ and CD4+ t-cell April - TraffikGen - gene/ car-t - peptide based May - AaviGen - heart - aav capsides June - GenAssist - muscle and CAR-T - aav based - 2nd generation June - TcellTech - CAR-T - CD19 cell As a result of these agreements, 3 share issues, and the company having received completely different financing, plans have evidently been affected, and no concrete results have been released. After updated data in heart and eye at the February 26th presentation (and the follow-up of this at ASGCT in May), no concrete results have actually been released. In e.g. CNS after the circVec 2.1 studies and the result in August 2025, things have stalled. They have said that the development between the circVec variants resembles the eye - continuously better effect with new circVec variants. The feasibility study has put a lid on results from 3.2 and 4.0 in CNS, which they were already working on last August. We only know that this is going better than expected. Disease models in eye and heart were in the pipeline. AAViGEN's fantastically precise AAV capsides in the heart have probably completely turned around the strategy in the heart project. Danon disease, which was on the agenda last autumn, is probably gone? It had no commercial purpose, about 1500 patients in the world -- it was only meant to document the circVec technology. Publication of CAR-T construct POC - has been postponed. It's not surprising when one looks at all the collaboration agreements across all the different variants in CAR-T and CAR-M. But - a CAR-T construct must exist, and it must have impressed several, as there has been a queue for collaboration and combining technologies. EYE - it is silent about, despite fantastic results 50x. They have talked about needing to conduct studies in primate species - monkeys or similar - to substantiate data. I believe a collaboration agreement will come there soon. We can interpret the silence as something being underway. We have indications that there has been contact for a long time between Circio and its collaboration partners before the agreements were announced. The technology has probably been tested/evaluated by both before an agreement was entered into. Among other things, in connection with the TraffikGen agreement that came at the end of April 2026, an article later appeared, published 2 months earlier in February 2026, which mentioned a collaboration with a Norwegian biotech company. Much has probably already been done in these collaborations. It looks like a busy autumn for Circio shareholders.
Supported @Bluebeam66 . If we get the results we believe and hope for, then it is exciting for us shareholders, but not least medically. - ·18 t sittenI have a question for those of you who have calculated the valuation of Circio. I see everything from 20–30 kroner to over 200 kroner per share being mentioned. Personally, I find it difficult to know what is actually realistic. For my part, a doubling from today's price around 7 would have been a very good investment. Should the company succeed properly, I think that 40–50 kroner would have been a fantastic outcome. So I am genuinely curious: What do you think is a realistic price target if the case succeeds? And perhaps even more importantly: How do you calculate it? Do you base it on comparable acquisitions like Orbital and Orna, expected licensing agreements, DCF, market size, or something completely different? I am most interested in the reasoning itself. It's easy to write a high number, but far more interesting to understand what assumptions lie behind it.
A license agreement with e.g. 20 mill dollar upfront payment will probably double the share price and more. Not primarily because of the money but because the probability of more agreements increases. At the same time, it strengthens the probability of an acquisition, and it validates the platform. All success criteria become more probable. 
·19 t sittenThose of you who have the roadmap available, what is the next trigger for crna? At least calendar-wise
This one has died out. The euphoria is gone. No stock exchange announcements and the turnover is drying up. Good to have moved over to oil. Will come back again when something happens. Good luck!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
91 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sittenWhen can we realistically expect data? Based on how similar preclinical collaborations normally develop (integration → in vitro → in vivo → analysis), my speculative timeline looks like this: Top-5 Pharma (CNS/AAV) Start: November 2025 Expectation: Q3–Q4 2026 University of Texas Start: January 2026 Expectation: Q4 2026 – Q1 2027 United Immunity (CAR-M) Start: March 2026 Expectation: Q4 2026 Acuitas (LNP/CAR-T) Start: April 2026 Expectation: Q4 2026 TraffikGene Start: April 2026 Expectation: Q1 2027 AaviGen (Heart) Start: May 2026 Expectation: Q4 2026 – Q1 2027 GenAssist Start: June 2026 Expectation: Q1–Q2 2027 Tcelltech Start: June 2026 Expectation: Q1 2027 ⸻ Why do I think this? The Top-5 Pharma collaboration is the best reference. It was announced in November 2025, went from in vitro to in vivo after around five months, and the company has guided towards updates in H2 2026. Looking at similar preclinical collaborations in biotech, it normally takes 6–12 months from when a collaboration is announced until the first meaningful in vivo data arrives. Complete datasets or publications often come later. My conclusion: H2 2026 will probably be the start of the news flow. 2027 could be the year when the majority of collaborations start to deliver results. This is only a qualified speculation based on normal development times in preclinical biotech and publicly available information – not the company's own guidance.There will probably be updates on sub-phases earlier than the "final" results. Many other things can also come besides these projects, I do not rule out updated circVec 5 with new functionalities, agreements etc.
- ·15 t sitten · MuokattuCircio is facing an autumn full of results. If one takes a look back in time, from when the news about the collaboration with Big Pharma came in November 2025 until July 2026, there are a few things that strike one. A number of news items about collaboration projects etc. have emerged, but limited concrete results have been released. New collaborations: Nov 2025 - Feasibility study CNS /AAVV 2026 January - University of Texas - vaccines/infectious diseases March - United Immunity - CAR-M cell therapy April - Acuitas - new LNP - CAR-T - CD8+ and CD4+ t-cell April - TraffikGen - gene/ car-t - peptide based May - AaviGen - heart - aav capsides June - GenAssist - muscle and CAR-T - aav based - 2nd generation June - TcellTech - CAR-T - CD19 cell As a result of these agreements, 3 share issues, and the company having received completely different financing, plans have evidently been affected, and no concrete results have been released. After updated data in heart and eye at the February 26th presentation (and the follow-up of this at ASGCT in May), no concrete results have actually been released. In e.g. CNS after the circVec 2.1 studies and the result in August 2025, things have stalled. They have said that the development between the circVec variants resembles the eye - continuously better effect with new circVec variants. The feasibility study has put a lid on results from 3.2 and 4.0 in CNS, which they were already working on last August. We only know that this is going better than expected. Disease models in eye and heart were in the pipeline. AAViGEN's fantastically precise AAV capsides in the heart have probably completely turned around the strategy in the heart project. Danon disease, which was on the agenda last autumn, is probably gone? It had no commercial purpose, about 1500 patients in the world -- it was only meant to document the circVec technology. Publication of CAR-T construct POC - has been postponed. It's not surprising when one looks at all the collaboration agreements across all the different variants in CAR-T and CAR-M. But - a CAR-T construct must exist, and it must have impressed several, as there has been a queue for collaboration and combining technologies. EYE - it is silent about, despite fantastic results 50x. They have talked about needing to conduct studies in primate species - monkeys or similar - to substantiate data. I believe a collaboration agreement will come there soon. We can interpret the silence as something being underway. We have indications that there has been contact for a long time between Circio and its collaboration partners before the agreements were announced. The technology has probably been tested/evaluated by both before an agreement was entered into. Among other things, in connection with the TraffikGen agreement that came at the end of April 2026, an article later appeared, published 2 months earlier in February 2026, which mentioned a collaboration with a Norwegian biotech company. Much has probably already been done in these collaborations. It looks like a busy autumn for Circio shareholders.Supported @Bluebeam66 . If we get the results we believe and hope for, then it is exciting for us shareholders, but not least medically.
- ·18 t sittenI have a question for those of you who have calculated the valuation of Circio. I see everything from 20–30 kroner to over 200 kroner per share being mentioned. Personally, I find it difficult to know what is actually realistic. For my part, a doubling from today's price around 7 would have been a very good investment. Should the company succeed properly, I think that 40–50 kroner would have been a fantastic outcome. So I am genuinely curious: What do you think is a realistic price target if the case succeeds? And perhaps even more importantly: How do you calculate it? Do you base it on comparable acquisitions like Orbital and Orna, expected licensing agreements, DCF, market size, or something completely different? I am most interested in the reasoning itself. It's easy to write a high number, but far more interesting to understand what assumptions lie behind it.A license agreement with e.g. 20 mill dollar upfront payment will probably double the share price and more. Not primarily because of the money but because the probability of more agreements increases. At the same time, it strengthens the probability of an acquisition, and it validates the platform. All success criteria become more probable.
- ·19 t sittenThose of you who have the roadmap available, what is the next trigger for crna? At least calendar-wiseThis one has died out. The euphoria is gone. No stock exchange announcements and the turnover is drying up. Good to have moved over to oil. Will come back again when something happens. Good luck!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
91 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sittenWhen can we realistically expect data? Based on how similar preclinical collaborations normally develop (integration → in vitro → in vivo → analysis), my speculative timeline looks like this: Top-5 Pharma (CNS/AAV) Start: November 2025 Expectation: Q3–Q4 2026 University of Texas Start: January 2026 Expectation: Q4 2026 – Q1 2027 United Immunity (CAR-M) Start: March 2026 Expectation: Q4 2026 Acuitas (LNP/CAR-T) Start: April 2026 Expectation: Q4 2026 TraffikGene Start: April 2026 Expectation: Q1 2027 AaviGen (Heart) Start: May 2026 Expectation: Q4 2026 – Q1 2027 GenAssist Start: June 2026 Expectation: Q1–Q2 2027 Tcelltech Start: June 2026 Expectation: Q1 2027 ⸻ Why do I think this? The Top-5 Pharma collaboration is the best reference. It was announced in November 2025, went from in vitro to in vivo after around five months, and the company has guided towards updates in H2 2026. Looking at similar preclinical collaborations in biotech, it normally takes 6–12 months from when a collaboration is announced until the first meaningful in vivo data arrives. Complete datasets or publications often come later. My conclusion: H2 2026 will probably be the start of the news flow. 2027 could be the year when the majority of collaborations start to deliver results. This is only a qualified speculation based on normal development times in preclinical biotech and publicly available information – not the company's own guidance.There will probably be updates on sub-phases earlier than the "final" results. Many other things can also come besides these projects, I do not rule out updated circVec 5 with new functionalities, agreements etc.
- ·15 t sitten · MuokattuCircio is facing an autumn full of results. If one takes a look back in time, from when the news about the collaboration with Big Pharma came in November 2025 until July 2026, there are a few things that strike one. A number of news items about collaboration projects etc. have emerged, but limited concrete results have been released. New collaborations: Nov 2025 - Feasibility study CNS /AAVV 2026 January - University of Texas - vaccines/infectious diseases March - United Immunity - CAR-M cell therapy April - Acuitas - new LNP - CAR-T - CD8+ and CD4+ t-cell April - TraffikGen - gene/ car-t - peptide based May - AaviGen - heart - aav capsides June - GenAssist - muscle and CAR-T - aav based - 2nd generation June - TcellTech - CAR-T - CD19 cell As a result of these agreements, 3 share issues, and the company having received completely different financing, plans have evidently been affected, and no concrete results have been released. After updated data in heart and eye at the February 26th presentation (and the follow-up of this at ASGCT in May), no concrete results have actually been released. In e.g. CNS after the circVec 2.1 studies and the result in August 2025, things have stalled. They have said that the development between the circVec variants resembles the eye - continuously better effect with new circVec variants. The feasibility study has put a lid on results from 3.2 and 4.0 in CNS, which they were already working on last August. We only know that this is going better than expected. Disease models in eye and heart were in the pipeline. AAViGEN's fantastically precise AAV capsides in the heart have probably completely turned around the strategy in the heart project. Danon disease, which was on the agenda last autumn, is probably gone? It had no commercial purpose, about 1500 patients in the world -- it was only meant to document the circVec technology. Publication of CAR-T construct POC - has been postponed. It's not surprising when one looks at all the collaboration agreements across all the different variants in CAR-T and CAR-M. But - a CAR-T construct must exist, and it must have impressed several, as there has been a queue for collaboration and combining technologies. EYE - it is silent about, despite fantastic results 50x. They have talked about needing to conduct studies in primate species - monkeys or similar - to substantiate data. I believe a collaboration agreement will come there soon. We can interpret the silence as something being underway. We have indications that there has been contact for a long time between Circio and its collaboration partners before the agreements were announced. The technology has probably been tested/evaluated by both before an agreement was entered into. Among other things, in connection with the TraffikGen agreement that came at the end of April 2026, an article later appeared, published 2 months earlier in February 2026, which mentioned a collaboration with a Norwegian biotech company. Much has probably already been done in these collaborations. It looks like a busy autumn for Circio shareholders.Supported @Bluebeam66 . If we get the results we believe and hope for, then it is exciting for us shareholders, but not least medically.
- ·18 t sittenI have a question for those of you who have calculated the valuation of Circio. I see everything from 20–30 kroner to over 200 kroner per share being mentioned. Personally, I find it difficult to know what is actually realistic. For my part, a doubling from today's price around 7 would have been a very good investment. Should the company succeed properly, I think that 40–50 kroner would have been a fantastic outcome. So I am genuinely curious: What do you think is a realistic price target if the case succeeds? And perhaps even more importantly: How do you calculate it? Do you base it on comparable acquisitions like Orbital and Orna, expected licensing agreements, DCF, market size, or something completely different? I am most interested in the reasoning itself. It's easy to write a high number, but far more interesting to understand what assumptions lie behind it.A license agreement with e.g. 20 mill dollar upfront payment will probably double the share price and more. Not primarily because of the money but because the probability of more agreements increases. At the same time, it strengthens the probability of an acquisition, and it validates the platform. All success criteria become more probable.
- ·19 t sittenThose of you who have the roadmap available, what is the next trigger for crna? At least calendar-wiseThis one has died out. The euphoria is gone. No stock exchange announcements and the turnover is drying up. Good to have moved over to oil. Will come back again when something happens. Good luck!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt